Alembic Pharmaceuticals announced Q1FY23 results: Alembic reports revenue for Q1 FY23 Rs. 1262 crore India Branded Business Ex of Covid-related products grew by an impressive 20%. International Generics Business de-grew by 3% to Rs. 549 crore Profit before tax for the quarter is Rs. 47 crore Mr. Shaunak Amin, Managing Director, Alembic Pharmaceuticals Limited said "India Branded Business continues to deliver robust numbers in Q1. India Business will witness market outperforming growth across most of the products and therapy areas in current year." Result PDF